Skip to content

IgG response against Staphylococcus aureus in patients with Netherton syndrome

IgG response against Staphylococcus aureus in patients with Netherton syndrome - IgGNS

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53242
Enrollment
12
Registered
2023-11-16
Start date
2023-11-22
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comel-Netherton Syndrome Netherton Syndrome

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
16 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Diagnosed with NS by an expert professional - Aged 16 years or above - Able to read patient information, fill out questionnaires and provide informed consent

Exclusion criteria

Exclusion criteria: - Systemic antibiotics within the previous 4 weeks - Topical antibiotics within the previous 7 days

Design outcomes

Primary

MeasureTime frame
- IgG antibody levels against S. aureus antigens, and a panel of other bacterial antigens (e.g. Pseudomonas aeruginosa, Streptococcus pneumoniae) measured in serum of NS patients using a Luminex assay, and compared to IgG antibody levels in healthy S. aureus carriers and non-carriers, AD patients and EB patients. - A list of S. aureus proteins produced in the skin of NS patients.

Secondary

MeasureTime frame
- Differences in IgG and IgG4 antibody levels in NS patients over time. - Identification and characterization of S. aureus (skin and nose) in NS patients.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)